REMEGEN (09995) is recommended to adopt the A-share stock incentive plan in 2023.
Connect global capital markets
REMEGEN (09995) announced that the board of directors recommends adopting the 2023 A-share stock incentive plan, planning to grant approximately 1.7831 million restricted stocks to the incentive beneficiaries. Upon the initial grant, 1.43245 million restricted stocks will be allocated, and approximately 0.3506 million restricted stocks will be reserved. The grant price (including reserved grants) is set at RMB 49.77 per A-share.
Related Articles
YZYBIO-B(02496): Fang Lijuan was elected as the workers' representative supervisor of the second session of the Supervisory Board.
TUYA-W(02391) issued 10,000 shares under the equity incentive plan.
EPS HEALTH TECH (03860) terminates acquisition of 16.23% of China Genetics' issued shares.
YZYBIO-B(02496): Fang Lijuan was elected as the workers' representative supervisor of the second session of the Supervisory Board.
TUYA-W(02391) issued 10,000 shares under the equity incentive plan.
EPS HEALTH TECH (03860) terminates acquisition of 16.23% of China Genetics' issued shares.
